Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual
Go back to Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual| (NYSE: OGN) | Delayed: 13.75 -0.01 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.76 | 52 Week High | $8.00 | |||
| Open | $13.75 | 52 Week Low | $8.00 | |||
| Day High | $13.77 | P/E | N/A | |||
| Day Low | $13.74 | EPS | $0.00 | |||
| Volume | 2,555,624 | |||||



